Results of a Phase II Open-Label Study of Capecitabine in Combination with Irinotecan as First-Line Treatment for Metastatic Colorectal Cancer

American Cancer Society

Ferlay

Levitan, 1993, Chemotherapy in colorectal cancer, Surg Clin North Am, 73, 167, 10.1016/S0039-6109(16)45936-0

Verschraegen, 1994, Medical management of colorectal carcinomas, Tumori, 80, 1, 10.1177/030089169408000101

Graf, 1994, The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer, Br J Cancer, 70, 559, 10.1038/bjc.1994.345

Leichman, 1993, Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer, J Natl Cancer Inst, 85, 41, 10.1093/jnci/85.1.41

Hansen, 1996, Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer, J Natl Cancer Inst, 88, 668, 10.1093/jnci/88.10.668

Van Cutsem, 2004, Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analysis from two large, randomized, phase III trials, Br J Cancer, 90, 1190, 10.1038/sj.bjc.6601676

Tewes, 2003, Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study, Ann Oncol, 14, 1442, 10.1093/annonc/mdg376

Bajetta, 2004, Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma, Cancer, 100, 279, 10.1002/cncr.11910

Kerr, 2002, Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials, Oncology (Huntingt), 16, 12

Furuta, 1991, Combination therapy of CPT-11, a camptothecine derivative, with various antitumour drugs against L1210 leukemia, Jpn J Cancer Chemotherapy, 18, 393

Cassata, 2001, Ongoing phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer (ACRC), Proc Am Soc Clin Oncol, 20, 144a

Patt YZ, Lin E, Leibmann J, et al. Capecitabine plus irinotecan: a highly active first-line treatment for metastatic colorectal cancer (MCRC). Presented at the 2005 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, FL. Abstract #228.

Grothey, 2003, Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs. capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC), Proc Am Soc Clin Oncol, 22, 255

Kerr, 2002, A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC), Proc Am Soc Clin Oncol, 21, 161a

Mori, 1993, Activity of continuousinfusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil, Cancer Chemother Pharmacol, 33, 179, 10.1007/BF00685339

Schuller, 1997, Tumor selectivity of Xeloda in colorectal cancer patients, Proc Am Soc Clin Oncol, 16, 227

Takebayashi, 1996, Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma, J Natl Cancer Inst, 88, 1110, 10.1093/jnci/88.16.1110

Grothey A. Capecitabine plus irinotecan in the treatment of advanced colorectal cancer. In: Advances in Colon Cancer, May 2004; 11-14.

Twelves, 2002, Capecitabine as firstline treatment in colorectal cancer. Pooled data from two large, phase III trials, Eur J Cancer, 38, 15, 10.1016/S0959-8049(01)00415-4